论文部分内容阅读
目的探讨还原型谷胱甘肽对原发性高血压患者高敏C反应蛋白(hsCRP)和血管内皮功能的影响。方法入选福建医科大学附属泉州第一医院心内科住院原发性高血压患者68例,随机分为两组:常规组:硝苯地平控释片(30mg/d)+依那普利(10mg,2次/d,n=34);实验组:常规组治疗+注射用还原型谷胱甘肽(2.4g/d,n=34);均治疗2周,分别于治疗前后测定hsCRP、内皮素和一氧化氮水平。结果与治疗前相比,两组治疗后hsCRP、内皮素水平均降低[常规组:hsCRP(3.6±0.9)比(3.8±0.9)mg/L,内皮素(64.1±11.2)比(67.4±10.8)ng/L,均P<0.05;实验组:hsCRP(3.2±0.8)比(3.8±0.9)mg/L,内皮素(58.8±9.2)比(67.9±10.3)ng/L;均P<0.05],实验组hsCRP、内皮素水平较常规组降低更明显[治疗前后hsCRP差值(0.6±1.0)比(0.2±0.5)mg/L,治疗前后内皮素差值(9.1±13.5)比(3.3±8.2)ng/L;P<0.05]。两组治疗后,一氧化氮水平均升高[常规组(58.3±10.5)比(54.2±10.5),实验组(63.7±10.4)比(53.6±9.9)mmol/L,P<0.05],实验组升高更明显[治疗前后一氧化氮差值(10.1±13.8)比(4.1±9.9)mmol/L;P<0.05]。结论还原型谷胱甘肽治疗可降低原发性高血压患者血清hsCRP和内皮素水平,提高一氧化氮水平。
Objective To investigate the effects of reduced glutathione on high sensitivity C-reactive protein (hsCRP) and endothelial function in patients with essential hypertension. Methods Sixty-eight inpatients with essential hypertension in Department of Cardiology, the First Affiliated Hospital of Quanzhou, Fujian Medical University were randomly divided into two groups: conventional group: nifedipine controlled release tablets (30mg / d) + enalapril (10mg, (2.4g / d, n = 34) for 2 weeks. The levels of hsCRP, endothelin And nitric oxide levels. Results Compared with those before treatment, hsCRP and ET decreased in both groups [hsCRP (3.6 ± 0.9) vs (3.8 ± 0.9) mg / L, endothelin (64.1 ± 11.2) vs (67.4 ± 10.8 (ng / L) ng / L, all P <0.05. In the experimental group, the ratio of hsCRP (3.2 ± 0.8) was 3.8 ± 0.9 mg / L and that of ET was (58.8 ± 9.2) ], The hsCRP and ET levels in the experimental group were significantly lower than those in the conventional group [(0.6 ± 1.0) vs (0.2 ± 0.5) mg / L before and after treatment), before and after treatment (9.1 ± 13.5) ± 8.2) ng / L; P <0.05]. The levels of nitric oxide in both groups were significantly higher than those in the control group (58.3 ± 10.5 vs 54.2 ± 10.5, 63.7 ± 10.4, 53.6 ± 9.9 mmol / L, P <0.05, respectively) Group increased more significantly [before and after treatment, the difference of nitric oxide (10.1 ± 13.8) than (4.1 ± 9.9) mmol / L; P <0.05]. Conclusion Reduced glutathione treatment can reduce serum hsCRP and endothelin levels and increase nitric oxide levels in patients with essential hypertension.